No profile data available.
Immunovant, Inc. (IMVT) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in Durham, United States, with about 315 full-time employees.
It reported revenue of $0 for fiscal year 2026, and net income of -$505.61 million. In Q1 2027 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $6.29 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2026; market data as of October 9, 2026.
, a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases.
Immunovant reported $0 in revenue for fiscal year 2026. In Q1 2027 revenue was $0.
$6.29 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include TG Therapeutics, Inc. (TGTX), Kiniksa Pharmaceuticals International, plc (KNSA), Aurinia Pharmaceuticals Inc. (AUPH), Viridian Therapeutics, Inc. (VRDN).